DIOSynVax Uses AI to Design Influenza Vaccines That Protect Against Multiple Strains
DIOSynVax, a clinical-stage biotech company, is developing influenza vaccines designed to work across multiple virus strains using artificial intelligence to identify which viral components trigger durable immune responses. The company presented its progress at the London Stock Exchange in June, showing that its pan-bird flu and supra-seasonal vaccines have passed safety and efficacy tests in animal models and are ready for human trials.
Traditional flu vaccines require annual reformulation because influenza mutates rapidly. DIOSynVax's approach targets conserved viral elements-parts that don't change as the virus evolves-to create cross-protection against multiple strains. A single vaccination could theoretically protect across multiple flu seasons, addressing a core limitation of current vaccines.
How the AI Platform Works
The company's Digital Immune Optimized Synthetic Vaccine technology uses AI to design vaccine antigens. The system rapidly identifies which viral components can trigger strong immune responses, then synthesizes vaccines based on those findings.
This data-driven method accelerates development timelines while improving safety and efficacy, according to the company. It represents a shift from conventional vaccine design, which typically targets specific virus variants rather than conserved structures.
What's Next
DIOSynVax is seeking funding and partnerships to move both vaccines into clinical trials. Dr Rebecca Kinsley, the company's chief operating officer, said appropriate funding would allow the company to generate "proof of concept data" needed for licensing trials.
The company is targeting three vaccine categories: a supra-seasonal flu vaccine, a pre-pandemic pan-bird flu vaccine, and eventually a universal influenza vaccine that works across all seasonal and pandemic strains.
For healthcare professionals tracking vaccine development and AI for Science & Research, this represents one approach to using machine learning in drug and vaccine design.
Your membership also unlocks:
